病態分子イメージングセンターに係る業績
講座等名iPS・幹細胞再生医学講座

事業推進者名人見浩史＜雑誌論文＞
1. Yamashita H, Fukuda K, Hattori F. Hepatocyte-like cells derived from human pluripotent stem cells can beenriched by combination of mitochondrial content and activated leukocyte cell adhesion molecule. JMAJournal. レフェリー有, 2019 in press.
2. Tamaki H, Ikegame K, Yoshihara S, Kaida K, Yoshihara K, Inoue T, Kato R, Nakata J, Fujioka T, Soma T,Okada M, Ogawa H. Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem celltransplantation with corticosteroid as graft-vs-host disease prophylaxis compared with cord bloodtransplantation. Transplant Infectious Disease.レフェリー有, e13073, 2019
3. Matsuoka Y, Sumide K, Sonoda Y. One-year Observation of the SCID-repopulating Cell Activities of
Human Cord Blood-derived CD34-positive and -negative Hematopoietic Stem Cells. Stem Cell Reviews andReports. レフェリー有, 2019 in press.
4. 松岡 由和、薗田 精昭. ヒト臍帯血由来造血幹細胞の陽性分子マーカーとしての GPI-80 抗原の有用性。Cytometry Research.レフェリー有, 228:13-17, 2018.
5. Matsuoka Y, Nakamura F, Hatanaka K, Fujioka T, Otani S, Kimura T, Fujimura Y, Asano H, Sonoda Y. The
number of CD34+CD133+ hematopoietic stem cell residing in umbilical cord blood units is not correlatedwith the number of total nucleated cells and CD34+ cells: A possible new indicator for quality evaluation ofUCB units. International Journal of Hematology. レフェリー有, 108:571-9, 2018
6. Sumide K, Matsuoka Y, Kawamura H, Nakatsuka R, Fujioka T, Asano H, Takihara Y, Sonoda Y. A Revised
Road Map for the Commitment of Human Cord Blood CD34-negative Hematopoietic Stem Cells. NatureCommunications レフェリー有, 9:2202, 2018.
7. Kawamura H, Nakatsuka R, Matsuoka Y, Sumide K, Fujioka T, Asano H, Sonoda Y. TGF-β Signaling
Accelerates Senescence of Human Bone-Derived CD271 and SSEA-4 Double-Positive Mesenchymal
Stromal Cells. Stem Cell Reports レフェリー有, 10:920-32, 2018.
8. Zhang Y, Nakano D, Guan Y, Hitomi H, Uemura A, Masaki T, Kobara H, Sugaya T, Nishiyama A. A
sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascularendothelial growth factor-dependent pathway after renal injury in mice. Kidney International レフェリー有, 94:524-35, 2018.
9. Wan N, Rahman A, Hitomi H, Nishiyama A. The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on
Sympathetic Nervous Activity. Frontiers in Endocrinology レフェリー有, 26;9:421, 2018.
10. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori
H, Nishiyama A. Effects of an SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system insubtotally nephrectomized rats. Journal of Pharmacological Sciences レフェリー有, 137:220-3, 2018.
11. Rahman A, Yamazaki D, Sufiun A, Kitada K, Hitomi H, Nakano D, Nishiyama A. A novel approach toadenine-induced chronic kidney disease associated anemia in rodents. PLoS One レ フ ェ リ ー 有 ,13:e0192531, 2018.
12. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus “Complications”. Hypertension
Research レフェリー有, 41:147-56, 2018.
13. Li L, Konishi Y, Morikawa T, Zhang Y, Kitabayashi C, Kobara H, Masaki T, Nakano D, Hitomi H, Kobori
H, Nishiyama A. Effects of an SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system insubtotally nephrectomized rats. Journal of Pharmacological Sciences レフェリー有, 137: 220-3, 2018.
14. Park SH, Uzawa T, Hattori F, Ogino S, Morimoto N, Tsuneda S, Ito Y. "All-in-one" in vitro selection ofcollagen-binding vascular endothelial growth factor. Biomaterials レフェリー有, 6:270-278, 2018.
15. Matsuoka Y, Takahashi M, Sumide K, Kawamura H, Nakatsuka R, Fujioka T, Sonoda Y. CD34 Antigen andthe MPL Receptor Expression Defines A Novel Class of Human Cord Blood-Derived Primitive
Hematopoietic Stem Cells. Cell Transplant レフェリー有, 26:1043-1058, 2017.
16. Sonoda Y. Human Hematopoietic Stem Cells: The Current Understanding and Future Prospects. Journal of
Hematopoietic Cell Transplantation レフェリー有, 6:70-83, 2017.
17. Hitomi H, Kasahara T, Katagiri N, Hoshina A, Mae S, Kotaka M, Toyohara T, Rahman A, Nakano D, Niwa
A, Saito M, Nakahata T, Nishiyama A, Osafune K. Human pluripotent stem cell-derived
erythropoietin-producing cells ameliorate renal anemia in mice. Science Translational Medicine レフェリ

ー有, 9:409, 2017.
18. Ansary TM, Fujisawa Y, Rahman A, Nakano D, Hitomi H, Kobara H, Masaki T, Titze JM, Kitada K,Nishiyama A. Responses of renal hemodynamics and tubular functions to acute sodium-glucose
cotransporter 2 inhibitor administration in non-diabetic anesthetized rats. Scientific Reports レフェリー有,7:9555, 2017.
19. Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A. Effect of a selective SGLT2 inhibitor,luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic
syndrome rats. Clinical and Experimental Pharmacology and Physiology レフェリー有, 44:522-5, 2017.
20. Hasan AU, Kittikulsuth W, Yamaguchi F, Ansary TM, Rahman A, Shibayama Y, Nakano D, Hitomi H,Tokuda M, Nishiyama A. IBMX protects human proximal tubular epithelial cells from hypoxic stressthrough suppressing hypoxia-inducible factor-1α expression. Experimental Cell Research レフェリー有,358:343-51, 2017.
21. Guan Y, Nakano D, Zhang Y, Li L, Liu W, Nishida M, Kuwabara T, Morishita A, Hitomi H, Mori K,Mukoyama M, Masaki T, Hirano K, Nishiyama A. A protease-activated receptor-1 antagonist protects
against podocyte injury in a mouse model of nephropathy. Journal of Pharmacological Sciences レフェリー有, 135:81-8, 2017.
22. Miyashita T, Inamoto R, Fukuda S, Hoshikawa H, Hitomi H, Kiyomoto H, Nishiyama A, Mori N. Hormonalchanges following a low-salt diet in patients with Ménière's disease. Auris Nasus Larynx レフェリー有,44:52-7, 2017.
23. Rahman A, Hitomi H, Nishiyama A. Cardioprotective effects of SGLT2 inhibitors are possibly associatedwith normalization of the circadian rhythm of blood pressure. Hypertension Research レフェリー有,40:535-40, 2017.
24. Hitomi H, Nishiyama A. How should we treat patients with primary aldosteronism to prevent new-onset
diabetes mellitus? Journal of Hypertensions. レフェリー有, 35:1575-6, 2017.
＜学会発表＞
1. 松 岡 由 和 , 角 出 啓 輔 , 中 塚 隆 介 , 白 水 泰 昌 , 藤 岡 龍 哉 , 薗 田 精 昭 , 服 部 文 幸 , 人 見 浩 史 .
CRISPR/Cas9 システムを用いたヒト造血幹細胞における CD34 抗原の発現意義の解析. 第 18 回日
本再生医療学会総会, 神戸市, 2019 年 3 月 21 日
2. 人見浩史. iPS 細胞由来細胞を用いた腎臓・内分泌領域創薬の新展開, 第 92 回日本薬理学会年会, 大阪市, 2019 年 3 月 14 日
3. 松岡由和, 中塚隆介, 藤岡龍哉. 機械学習による血球細胞の自動判別システム. 第 80 回日本血液学会, 大阪市, 2018 年 10 月 13 日
4. 薗田精昭. ヒト造血幹細胞の最新知見-ヒト造血幹細胞の純化と階層制の解明-第 80 回日本血液学会, 大阪市, 2018 年 10 月 12 日
5. 人見浩史. iPS 細胞を用いた慢性腎不全の次世代治療法, 第 48 回日本腎臓学会西部学術大会, 徳島市, 2018 年 9 月 28 日
6. 松岡由和. Automatic discrimination system for hematopoietic tumor-derived cell lines using MachineLearning. 第 77 回日本癌学会, 大阪市, 2018 年 9 月 27 日
7. 人見浩史, 西山成, 長船健二. iPS 細胞を用いて腎性貧血を治療する, 第 63 回日本透析医学会学術集会, 神戸市, 2018 年 6 月 30 日
8. 人見浩史, 笠原朋子, 片桐直子, 保科あずさ, 前伸一, 小髙真希, 豊原敬文, Asadur Rahman, 中野大介, 丹羽明, 斎藤潤, 中畑龍俊, 西山成, 長船健二. iPS 細胞由来エリスロポエチン産生細胞を用いた腎性貧血に対する細胞療法開発, 第 61 回日本腎臓学会学術総会, 新潟市, 2018 年 6 月 10 日
9. 松岡由和、角出啓輔、中塚隆介、藤岡龍哉、薗田精昭. 重症免疫不全マウスにおける継代移植を用いないヒト造血幹細胞活性の長期解析. 第 28 回日本サイトメトリー学会, 東京都, 2018 年 5 月 26日
10. Hirofumi Hitomi, Daisuke Nakano, Kenji Osafune, Akira Nishiyama. Human pluripotent stem cell-derived
erythropoietin-producing cells improve renal anemia in mice, WCP2018, Kyoto, Japan, 2018 年 7 月 4 日
11. Hirofumi Hitomi, Tomoko Kasahara, Naoko Katagiri, Azusa Hoshina, Shin-Ichi Mae, Maki Kotaka,Takafumi Toyohara, Asadur Rahman, Daisuke Nakano, Akira Niwa, Megumu K. Saito, Tatsutoshi Nakahata,Akira Nishiyama, Kenji Osafune. Human pluripotent stem cell-derived erythropoietin-producing cells
improve renal anemia in mice, ISSCR 2018 Annual Meeting, Melbourne, Australia, 2018 年 6 月 21 日